8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05655520 (ClinicalTrials.gov) | December 14, 2022 | 9/12/2022 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | Huntington Disease | Drug: SAGE-718 | Sage Therapeutics | NULL | Recruiting | 25 Years | 65 Years | All | 300 | Phase 3 | United States |
| 2 | NCT05358821 (ClinicalTrials.gov) | June 22, 2022 | 27/4/2022 | A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | Huntington Disease | Drug: SAGE-718;Drug: Placebo | Sage Therapeutics | NULL | Recruiting | 25 Years | 65 Years | All | 80 | Phase 2 | United States |
| 3 | NCT05107128 (ClinicalTrials.gov) | February 10, 2022 | 25/10/2021 | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease | Huntington's Disease | Drug: SAGE-718;Drug: Placebo | Sage Therapeutics | NULL | Recruiting | 25 Years | 65 Years | All | 178 | Phase 2 | United States;Australia;Canada;United Kingdom |
| 4 | NCT03787758 (ClinicalTrials.gov) | February 28, 2019 | 17/12/2018 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease | Huntington Disease | Drug: SAGE-718 | Sage Therapeutics | NULL | Completed | 18 Years | 70 Years | All | 6 | Phase 1 | United States |